Patents by Inventor Masahiro Amakawa
Masahiro Amakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9034906Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.Type: GrantFiled: September 26, 2014Date of Patent: May 19, 2015Assignees: Asahi Glass Company, Limited, Kaken Pharmaceutical Co., Ltd.Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
-
Publication number: 20150018401Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.Type: ApplicationFiled: September 26, 2014Publication date: January 15, 2015Inventors: Takahiko MURATA, Masahiro AMAKAWA, Shin TERADAIRA, Yasushi MATSUMURA, Katsuhiko KONISHI
-
Patent number: 8877787Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.Type: GrantFiled: January 9, 2014Date of Patent: November 4, 2014Assignees: Asahi Glass Company, Limited, Kaken Pharmaceutical Co., Ltd.Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
-
Publication number: 20140128441Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.Type: ApplicationFiled: January 9, 2014Publication date: May 8, 2014Applicants: Kaken Pharmaceutical Co., Ltd., Asahi Glass Company, LimitedInventors: Takahiko MURATA, Masahiro AMAKAWA, Shin TERADAIRA, Yasushi MATSUMURA, Katsuhiko KONISHI
-
Patent number: 8691857Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.Type: GrantFiled: November 13, 2012Date of Patent: April 8, 2014Assignees: Asahi Glass Company, Ltd., Kaken Pharmaceutical Co., Ltd.Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
-
Patent number: 8394844Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1 -4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.Type: GrantFiled: November 2, 2010Date of Patent: March 12, 2013Assignees: Asahi Glass Company, Limited, Kaken Pharmaceutical Co., Ltd.Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
-
Publication number: 20110098481Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.Type: ApplicationFiled: November 2, 2010Publication date: April 28, 2011Applicants: ASAHI GLASS COMPANY, LIMITED, KAKEN PHARMACEUTICAL CO., LTD.Inventors: Takahiko MURATA, Masahiro AMAKAWA, Shin TERADAIRA, Yasushi MATSUMURA, Katsuhiko KONISHI
-
Publication number: 20080249144Abstract: Not only acute or chronic interstitial pneumonia and plumonary fibrosis but also chronic obstructive plumonary diseases, such as plumonary emphysema and chronic bronchitis, can be effectively prevented or treated by inhalation administration to the lung tissue of 2-{N-[4-(4-chlorobenzenesulfonylamino)butyl]-N-{3-[(4-isopropyl 2-thiazolyl)methoxy]benzyl}}-sulfamoylbenzoic acid or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: July 21, 2005Publication date: October 9, 2008Applicant: KAKEN PHARMACEUITICAL CO., LTD.Inventors: Toshiaki Okuda, Shigeo Kurokawa, Takahiko Murata, Masahiro Amakawa, Tsutomu Nakamura
-
Patent number: 6849597Abstract: An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.Type: GrantFiled: December 28, 2000Date of Patent: February 1, 2005Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Takahiko Murata, Tadashi Ohyama, Masahiro Amakawa, Keiko Fujita, Haruyoshi Ueo
-
Publication number: 20050014675Abstract: An agent for prevention or treatment of vascular disease and renal dysfunction that are accompanied by the migration of vascular smooth muscle cells and mesangial cells comprises as an active ingredient a growth-hormone secretion promoting substance receptor agonist that have a strong inhibitory action on the migration of vascular smooth muscle cells and mesangial cells. Using such an agent for prevention or treatment, one can suppress arteriosclerosis, recurrence of intimal thickening after angioplasty, and even glomerulosclerosis.Type: ApplicationFiled: December 5, 2002Publication date: January 20, 2005Inventors: Masahiro Amakawa, Takahiko Murata
-
Publication number: 20030100494Abstract: An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.Type: ApplicationFiled: June 27, 2002Publication date: May 29, 2003Inventors: Takahiko Murata, Tadashi Ohyama, Masahiro Amakawa, Keiko Fujita, Haruyoshi Ueo
-
Patent number: 6046164Abstract: The present invention relates to a method for treating diseases of periodontal tissue by administering a basic fibroblast growth factor, by which the tissue injury is treated to induce regeneration, curing or new attachment.Type: GrantFiled: May 24, 1995Date of Patent: April 4, 2000Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Taiji Asano, Hajime Sugimoto, Akio Terashima, Yoshiko Nakano, Masahiro Amakawa, Katumasa Saga